« Previous
Next »
The Journal of Pediatrics
Volume 156, Issue 5
, Pages 798-803.e2
, May 2010
From Regulatory Problems in Infancy to Attention-Deficit/Hyperactivity Disorder in Childhood: A Moderating Role for the Dopamine D4 Receptor Gene?
References
- . A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry. 1999;56:1073–1086
- . Pharmacotherapy of attention-deficit/hyperactivity disorder in adults. J Clin Psychiatry. 1998;59(Suppl 7):76–79
- . Development and prediction of hyperactive symptoms from 2 to 7 years in a population-based sample. Pediatrics. 2006;117:2101–2110
- . Persistent infant crying and hyperactivity problems in middle childhood. Pediatrics. 2002;109:1054–1060
- . Long-term cognitive development in children with prolonged crying. Arch Dis Child. 2004;89:989–992
- . Severe sleep problems in infancy associated with subsequent development of attention-deficit/hyperactivity disorder at 5.5 years of age. Acta Paediatr. 2002;91:584–592
- . Are regulatory problems in infancy precursors of later hyperkinetic symptoms?. Acta Paediatr. 2004;93:1463–1469
- . Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry. 2005;57:1215–1220
- Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57:1313–1323
- Polymorphisms of the dopamine D4 receptor, clinical outcome, and cortical structure in attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2007;64:921–931
- . Dopaminergic polymorphisms and regulatory problems in infancy. Z Kinder Jugendpsychiatr Psychother. 2007;35:145–151(in German)
- . Developmental outcome of infants born with biological and psychosocial risks. J Child Psychol Psychiatry. 1997;38:843–853
- Behavioral sequelae of perinatal insults and early family adversity at 8 years of age. J Am Acad Child Adolesc Psychiatry. 2000;39:1229–1237
- . Temperament and Development. New York: Brunner/Mazel; 1977;
- . Temperament and Behavior Disorders in Children. New York: University Press; 1968;
- . Adverse temperamental characteristics and early behaviour problems in 3-month-old infants born with different psychosocial and biological risks. Acta Paedopsychiatr. 1993;56:19–24
- . Mannheim Parent Interview: Structured Interview for Child Psychiatric Disorders. Weinheim, Germany: Beltz; 1989;(in German)
- . Diagnostic appraisal and interviewing. In: Rutter M, Hersov L editor. Child and Adolescent Psychiatry: Modern Approaches. 2nd ed. Oxford, UK: Blackwell; 1985;p. 233–284
- . Atypical frontal brain activation in ADHD: preschool and elementary school boys and girls. J Am Acad Child Adolesc Psychiatry. 1999;11:1363–1371
- . Association of dopamine D4 receptor (DRD4) gene with attention-deficit/hyperactivity disorder (ADHD) in a high-risk community sample: a longitudinal study from birth to 11 years of age. J Neural Transm. 2004;111:883–889
- . Epidemiology and course of psychiatric disorders in school-age children: results of a longitudinal study. J Child Psychol Psychiatry. 1990;31:243–263
- . Differential development of infants at risk for psychopathology: the moderating role of early maternal responsivity. Dev Med Child Neurol. 2001;43:292–300
- Delmo C, Weiffenbach O, Gabriel M, Poustka F. Kiddie SADS, Present and Lifetime version (KSADS-Pl). Available from: www.klinik.uni-frankfurt.de/zpsy/kinderpsychiatrie/ksadspl.html. Accessed .
- . A hypervariable segment in the human dopamine receptor D4 (DRD4) gene. Hum Mol Genet. 1993;2:767–773
- . Functional polymorphisms in dopamine and serotonin pathway genes. Hum Mutat. 2006;27:1–13
- . DRD4 related to infant attention and information processing: a developmental link to ADHD?. Psychiatr Genet. 2001;11:31–35
- Association of dopamine D4 receptor (DRD4) exon III repeat polymorphism with temperament in 3-year-old infants. Neurogenetics. 2003;4:207–212
- . Visual exploratory behaviour in infancy and novelty seeking in adolescence: two developmentally specific phenotypes of DRD4?. J Child Psychol Psychiatry. 2006;47:1143–1151
- . The association of the dopamine D4 receptor gene (DRD4) and the serotonin transporter promoter gene (5-HTTLPR) with temperament in 12-month-old infants. J Child Psychol Psychiatry. 2001;42:777–783
- . A meta-analysis of the association between DRD4 polymorphism and novelty seeking. Mol Psychiatry. 2002;7:712–717
- . Gene-environment interaction of the dopamine D4 receptor (DRD4) and observed maternal insensitivity predicting externalizing behavior in preschoolers. Dev Psychobiol. 2006;48:406–409
- . Experimental evidence for differential susceptibility: dopamine D4 receptor polymorphism (DRD4 VNTR) moderates intervention effects on toddlers' externalizing behavior in a randomized controlled trial. Dev Psychol. 2008;44:293–300
- . Zero to Three: Diagnostic Classification of Mental Health and Developmental Disorders of Infancy and Early Childhood. Arlington, VA: National Center for Clinical Infant Programs; 1994;p. 31-8
- Association of D4 dopamine receptor gene and serotonin transporter promoter polymorphisms with infants' response to novelty. Mol Psychiatry. 2003;8:90–97
- . Genetic associations: false or true?. Trends Mol Med. 2003;9:135–138
- . Precursors of hyperactive disorders: potential early diagnosis in infants?. Z Kinder Jugendpsychiatr Psychother. 2007;35:179–188(in German)
Supported in part by grants from the Deutsche Forschungsgemeinschaft as part of the Special Research Program SFB 258, “Indicators and Risk Models of the Genesis and Course of Mental Disorders,” at the University of Heidelberg. The study sponsor had no input into the study design, data collection, or writing of the manuscript. K.B. is/has been involved in research/clinical trials with Eli Lilly and Shire, is on the advisory board of Eli Lilly Germany, serves on the speaker bureaus of Eli Lilly and Astra Zeneca, and has received conference attendance support from Shire. T.B. has served in an advisory or consultancy role for Lilly, Medice, Novartis, Pfizer, Shire, and UCB and has received conference attendance support or has been paid for public speaking by Lilly, Janssen McNeil, Medice, Novartis, and UCB. M.E.-F. has been paid for public speaking by Astra Zeneca and has participated in clinical trials with Eli Lilly, Novartis, and Janssen-Cilag. The other authors declare no conflicts of interest.
PII: S0022-3476(09)01228-1
doi: 10.1016/j.jpeds.2009.12.005
© 2010 Mosby, Inc. All rights reserved.
« Previous
Next »
The Journal of Pediatrics
Volume 156, Issue 5
, Pages 798-803.e2
, May 2010
